US third party inspection plan takes shape as nominees are listed
This article was originally published in Clinica
Executive Summary
The FDA has released the names of the15 companies that will be authorised to perform quality systems inspections in lieu of the FDA in the first year of the agency's third party inspection programme. The companies selected to fill this year's 15 available slots were chosen from a list of 18 that met the agency's minimum criteria for acceptance out of 23 total applicants. To qualify, companies could have no ownership stake in any FDA-regulated company and their staff had to meet the same academic qualifications as comparable FDA officials (see Clinica No 1080, p 1).
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.